Strategic Demonstration of the Clinical Utility of Nontraditional Antibacterials.

Antimicrobial stewardship (AMS) interventions have curbed antibiotic misuse, paradoxically restricting market adoption of new antibiotics in the process. This review critically examines non-traditional approaches to manage bacterial infections, offering solutions to reinforce AMS without compromising the commercial viability of thes new agents. An analysis of the key value propositions, regulatory frameworks, and market access pathways is presented. Actionable strategies to overcome regulatory and commercial challenges towards integrating non-traditional agents into clinical guidelines and AMS policies are highlighted.

• Publication year

  2025

• Venue

  Infectious Disease Clinics of North America

• Publication date

  2025-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.idc.2025.11.006PMID 41419397
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bacteriophage Therapy: Discovery, Development, and FDA Approval Pathways

  2025cited by this paper
• Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria

  2025cited by this paper
• Antibiotics re-booted—time to kick back against drug resistance

  2025cited by this paper
• Incidence and prevalence of antimicrobial resistance in outpatients with cancer: a multicentre, retrospective, cohort study.

  2025cited by this paper
• Emerging antimicrobial therapies for Gram-negative infections in human clinical use

  2025cited by this paper
• Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050

  2024cited by this paper
• Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

  2024cited by this paper
• Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study

  2024cited by this paper
• Overcoming challenges in the economic evaluation of interventions to optimise antibiotic use

  2024cited by this paper
• When Antimicrobial Treatment and Surgical Prophylaxis Collide: A Stewardship Opportunity

  2024cited by this paper
• Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT).

  2024cited by this paper
• New clinical trial design in precision medicine: discovery, development and direction

  2024cited by this paper
• Burden of Antimicrobial Resistance in Adult Hospitalized Patients With Cancer: A Multicenter Analysis

  2024cited by this paper
• Navigating performance measures for ambulatory antimicrobial stewardship: a review of HEDIS® and other metrics the steward should know

  2024cited by this paper
• CDC’s Core Elements to promote diagnostic excellence

  2024cited by this paper
• Current status of bacteriophage therapy for severe bacterial infections

  2024cited by this paper
• A retrospective, observational study of 12 cases of expanded access customized phage therapy: production, characteristics, and clinical outcomes.

  2023cited by this paper
• Antibiotic adjuvants: synergistic tool to combat multi-drug resistant pathogens

  2023cited by this paper
• ASHP/SIDP Joint Statement on the Pharmacist's Role in Antimicrobial Stewardship.

  2023cited by this paper
• Leveraging Health Systems to Expand and Enhance Antibiotic Stewardship in Outpatient Settings.

  2023cited by this paper
• Moving beyond mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.

  2023cited by this paper
• Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice

  2023cited by this paper
• Antimicrobial Stewardship at Transitions of Care to Outpatient Settings: Synopsis and Strategies

  2022cited by this paper
• Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial

  2022cited by this paper
• A Baker’s Dozen of Top Antimicrobial Stewardship Intervention Publications in Non–Hospital Care Settings in 2021

  2022cited by this paper
• Antimicrobial Challenge in Acute Care Surgery

  2022cited by this paper
• Improving Traditional Registrational Trial Endpoints: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Complicated Urinary Tract Infection Clinical Trials.

  2022cited by this paper
• Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults.

  2022cited by this paper
• Antibiotic stewardship in direct-to-consumer telemedicine consultations lead to high adherence to best practice guidelines and a low prescription rate.

  2021cited by this paper
• Economic Evaluations of New Antibiotics: The High Potential Value of Reducing Healthcare Transmission Through Decolonization.

  2021cited by this paper
• The Impact of Infections on Reimbursement in 92 US Hospitals, 2015-2018.

  2021cited by this paper
• Opportunities to Improve Antibiotic Prescribing in Outpatient Hemodialysis Facilities: A Report From the American Society of Nephrology and Centers for Disease Control and Prevention Antibiotic Stewardship White Paper Writing Group

  2020cited by this paper
• Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States

  2020cited by this paper
• A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development

  2020cited by this paper
• Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus

  2020cited by this paper
• Barriers and facilitators to the uptake of an antimicrobial stewardship program in primary care: A qualitative study

  2020cited by this paper
• Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies

  2020cited by this paper
• Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug

  2020cited by this paper
• Designing development programs for non-traditional antibacterial agents

  2019cited by this paper
• Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review

  2019cited by this paper
• Antibiotic development — economic, regulatory and societal challenges

  2019cited by this paper
• One Size Fits All? Application of Susceptible-Dose-Dependent Breakpoints to Pediatric Patients and Laboratory Reporting

  2019cited by this paper
• Combating resistance while maintaining innovation: the future of antimicrobial stewardship.

  2019cited by this paper
• Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials.

  2019cited by this paper
• Non-traditional Antibacterial Therapeutic Options and Challenges.

  2019cited by this paper
• Advantages and Limitations of Bacteriophages for the Treatment of Bacterial Infections

  2019cited by this paper
• The Magistral Phage

  2018cited by this paper
• Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence

  2018cited by this paper
• Studying new antibiotics for multidrug resistant infections: are today’s patients paying for unproved future benefits?

  2018cited by this paper
• Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis.

  2017cited by this paper
• Challenges and Opportunities of Nontraditional Approaches to Treating Bacterial Infections

  2017cited by this paper
• Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance

  2017cited by this paper
• Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.

  2016cited by this paper
• Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.

  2016cited by this paper
• Systematic Review and Meta-analysis of Clinical and Economic Outcomes from the Implementation of Hospital-Based Antimicrobial Stewardship Programs

  2016cited by this paper
• Policy Statement on Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)

  2012cited by this paper
• Biomarkers and surrogate endpoints in clinical trials

  2012cited by this paper
• A paradigm shift in drug development for treatment of rare multidrug-resistant gram-negative pathogens.

  2012cited by this paper
• Why is big Pharma getting out of antibacterial drug discovery?

  2003cited by this paper
• The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure

  1996cited by this paper
• Annals of the New York Academy of Sciences the Evolution of the Regulatory Framework for Antibacterial Agents

  year unknowncited by this paper

• No citing papers are available for this paper.